Which statement reflects common indications for initiating biologic therapy in IBD?

Which statement reflects common indications for initiating biologic therapy in IBD?

• A. Moderate-to-severe disease despite conventional therapy; steroid-refractory disease; fistulizing Crohn's; extraintestinal manifestations
• B. Mild disease not requiring steroids
• C. When disease resolves spontaneously
• D. Only after surgical cure

Answer: (A)

Biologic therapy in IBD is generally reserved for patients whose disease remains active or is complicated despite conventional treatments, or who have certain challenging features. When inflammation stays uncontrolled despite standard options like corticosteroids or immunomodulators, using biologics aims to induce and maintain remission and often to spare the patient from long-term steroid use. If the disease is steroid-refractory, meaning steroids fail to control symptoms, biologics offer a more targeted and effective alternative. Fistulizing Crohn’s disease presents a difficult complication where biologics can help promote fistula closure and reduce drainage. Extraintestinal manifestations—such as joint, skin, or eye involvement—that accompany IBD can also improve with systemic biologic therapy because these drugs address inflammatory pathways active both in the gut and in other tissues. In contrast, mild disease that doesn’t require steroids is typically managed with less aggressive therapies; if the disease resolves on its own, there’s no need for biologics. Waiting for spontaneous resolution or proceeding only after surgical cure ignores the goal of controlling inflammation early and preventing complications, including surgery.

Biologic therapy in IBD is generally reserved for patients whose disease remains active or is complicated despite conventional treatments, or who have certain challenging features. When inflammation stays uncontrolled despite standard options like corticosteroids or immunomodulators, using biologics aims to induce and maintain remission and often to spare the patient from long-term steroid use. If the disease is steroid-refractory, meaning steroids fail to control symptoms, biologics offer a more targeted and effective alternative. Fistulizing Crohn’s disease presents a difficult complication where biologics can help promote fistula closure and reduce drainage. Extraintestinal manifestations—such as joint, skin, or eye involvement—that accompany IBD can also improve with systemic biologic therapy because these drugs address inflammatory pathways active both in the gut and in other tissues.

In contrast, mild disease that doesn’t require steroids is typically managed with less aggressive therapies; if the disease resolves on its own, there’s no need for biologics. Waiting for spontaneous resolution or proceeding only after surgical cure ignores the goal of controlling inflammation early and preventing complications, including surgery.